Alzheimer’s disease-related innovations

September 21 is World Alzheimer’s Day. Alzheimer’s Disease is the most common cause of dementia, accounting for up to 80% of all dementia cases. Even with that staggering number, more than 80% of Americans know little or are not familiar with mild cognitive impairment (MCI), which can be an early stage of Alzheimer’s. 

Today we are sharing two innovations related to Alzheimer’s disease discovered by Purdue University researchers. They have disclosed these innovations to the Purdue Research Foundation Office of Technology Commercialization: 

Reporter Molecule for Study of Alzheimer’s Disease 

Gaurav Chopra, the Associate Professor of Analytical and Physical Chemistry, leads a team that has developed pH-dependent fluorescent analogue of the protein that is accumulated in Alzheimer’s disease to visualize its degradation and clearance by specialized cells. 

This technology promises to aid in the discovery of new therapeutics for Alzheimer’s disease. 

Small Molecule Proteasome Stimulators of Proteasome for Protein Degradation to Treat Alzheimer’s and Parkinson’s Diseases 

Darci J. Trader, the Assistant Professor of Medicinal Chemistry and Molecular Pharmacology, leads a team that has developed a pharmaceutical intervention to degrade the damaged and disordered proteins associated with a variety of diseases including Alzheimer’s and Parkinson’s.  

Are you interested in learning more about developing or commercializing the innovations listed above or others in OTC’s Biomedical Engineering, Medical/Health and Pharmaceuticals categories? The best next step is to contact OTC via email at